Literature DB >> 9339682

Pigmentary retinopathy associated with the mitochondrial DNA 3243 point mutation.

C M Sue1, P Mitchell, D S Crimmins, C Moshegov, E Byrne, J G Morris.   

Abstract

Fourteen patients from four unrelated families were studied to determine the prevalence of retinal pigmentary abnormalities associated with the MELAS A to G 3243 point mutation. Neurologic and ophthalmic examinations, retinal photography, pattern shift visual evoked potentials, and electroretinography were performed in all patients. Eight of the 14 patients had retinal pigmentary abnormalities characterized by symmetric areas of depigmentation involving predominantly the posterior pole and midperipheral retina. None of the patients had optic atrophy and only one patient with pigmentary retinal abnormalities had impaired visual acuity. None of the diabetic subjects (n = 6) had signs of diabetic retinopathy. Fluorescein angiography demonstrated mottled hyper- and hypofluorescent areas indicating multiple window defects in the retinal pigmentary epithelium. Visual evoked potentials showed delayed P100 responses in four of the eight patients with retinal pigmentary abnormalities. We conclude that there is a high prevalence of retinal pigmentary abnormalities in patients with MELAS A to G 3243 point mutation. These abnormalities are usually asymptomatic and best detected by retinal photography.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9339682     DOI: 10.1212/wnl.49.4.1013

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.

Authors:  G B Arden
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

Review 2.  Macular pattern dystrophy and homonymous hemianopia in MELAS syndrome.

Authors:  Radua Kamal-Salah; Isabel Baquero-Aranda; María Del Mar Grana-Pérez; Jose Manuel García-Campos
Journal:  BMJ Case Rep       Date:  2015-03-12

3.  Retinitis pigmentosa and progressive sensorineural hearing loss caused by a C12258A mutation in the mitochondrial MTTS2 gene.

Authors:  F C Mansergh; S Millington-Ward; A Kennan; A S Kiang; M Humphries; G J Farrar; P Humphries; P F Kenna
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 4.  Mitochondrial disorders and the eye.

Authors:  Nicole J Van Bergen; Rahul Chakrabarti; Evelyn C O'Neill; Jonathan G Crowston; Ian A Trounce
Journal:  Eye Brain       Date:  2011-09-26

Review 5.  Spare the rod and spoil the eye.

Authors:  G B Arden; R L Sidman; W Arap; R O Schlingemann
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

Review 6.  Retinitis pigmentosa, pigmentary retinopathies, and neurologic diseases.

Authors:  M Tariq Bhatti
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

Review 7.  An Eye on Movement Disorders.

Authors:  Duncan Wilson; Mark Hallett; Tim Anderson
Journal:  Mov Disord Clin Pract       Date:  2021-08-10

8.  Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population.

Authors:  K Majamaa; J S Moilanen; S Uimonen; A M Remes; P I Salmela; M Kärppä; K A Majamaa-Voltti; H Rusanen; M Sorri; K J Peuhkurinen; I E Hassinen
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 9.  Aging is not a disease: distinguishing age-related macular degeneration from aging.

Authors:  Daniel Ardeljan; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2013-08-09       Impact factor: 21.198

10.  Mitochondrial haplogroups and control region polymorphisms in age-related macular degeneration: a case-control study.

Authors:  Edith E Mueller; Elena Schaier; Susanne M Brunner; Waltraud Eder; Johannes A Mayr; Stefan F Egger; Christian Nischler; Hannes Oberkofler; Herbert A Reitsamer; Wolfgang Patsch; Wolfgang Sperl; Barbara Kofler
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.